Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Nov 15 - Nov 20
Retatrutide has developed one of the most rapidly growing pre-clinical research profiles of any metabolic peptide currently in active study: Pre-clinical metabolic research in obese animal models has reported body weight and fat mass reductions with Retatrutide that exceed those observed with dual-receptor compounds including Tirzepatide at comparable doses and suggesting that the addition of glucagon receptor engagement to combined GLP-1/GIP agonism produces meaningfully greater metabolic effects in experimental settings
A Familiar Pen Injector at an Affordable Price The Envoi TM Pen Injector is a compact and user-friendly pen device designed for the subcutaneous delivery of medication
"Drug makers' prices for these medications are putting a big burden on our employer customers," said McHugh
This triple mechanism of action distinguishes it from existing approved agents such as semaglutide (a GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist)
